

DAFTAR PUSTAKA

- Almasri, H. A., Soliman, A. T., De Sanctis, V., Alsaud, A. E., Alhashimy, R., Babikir, M. M., Ahmad, R. T., Aldwairi, M. M., Kloub, M. N., Ahmed, S., Al-Tikrity, M. A., Eisa, M. S., & Yassin, M. A. (2022). Prevalence and Significance of Leukopenia Induced by Intravenous Iron Therapy in a Large Cohort of Females with Iron Deficiency Anemia (IDA). *Acta Bio Medica : Atenei Parmensis*, **93**(2), e2022183.
- Anderson, P. O., Knoben, J. E., & Troutman, W. G. (Eds.). (2002). *Handbook of clinical drug data* (10. ed). McGrawHill, Medical Publ. Division.
- Ang, D. J. M., & Chan, J. J. (2024). Evolving standards and future directions for systemic therapies in cervical cancer. *Journal of Gynecologic Oncology*, **35**(2), e65.
- Awosika, A. O., Farrar, M. C., & Jacobs, T. F. (2026). Paclitaxel. In *StatPearls*. StatPearls Publishing.
<http://www.ncbi.nlm.nih.gov/books/NBK536917/>
- Berta, D. M., Teketelew, B. B., Chane, E., Bayleyegn, B., Tamir, M., Cherie, N., Seyoum, M., Mekuanint, A., & Aynalem, M. (2024). Hematological changes in women with cervical cancer before and after cancer treatment: Retrospective cohort study. *Scientific Reports*, **14**(1), 27630.
- Bhattacharjee, R., Dey, T., Kumar, L., Kar, S., Sarkar, R., Ghorai, M., Malik, S., Jha, N. K., Vellingiri, B., Kesari, K. K., Pérez de la Lastra, J. M., & Dey, A. (2022). Cellular landscaping of cisplatin resistance in cervical cancer. *Biomedicine & Pharmacotherapy*, **153**, 113345.
- BPOM RI, D. (2012). *Direktorat Pengawasan Distribusi Produk Terapeutik Dan Pkrt Badan Pom RI Jakarta 2012*.
- Bray, F. (2025). *Global Cancer Observatory*. <https://gco.iarc.who.int/en>
- Chavez, J. D., Keller, A., Zhou, B., Tian, R., & Bruce, J. E. (2019). Cellular Interactome Dynamics during Paclitaxel Treatment. *Cell Reports*, **29**(8), 2371-2383.e5.
- Common terminology criteria for adverse events—UpToDate*. (2025). Retrieved July 8, 2025, from <https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events>
- Crosbie, E. J., Einstein, M. H., Franceschi, S., & Kitchener, H. C. (2013). Human papillomavirus and cervical cancer. *The Lancet*, **382**(9895), 889–899.
- Danil, N., Arifuddin, S., Hartono, E., Rakhmah, N., Ajardiana, A., Rauf, S., & Zainuddin, A. A. (2023). Perbandingan Respon Terapi dan Toksisitas Regimen Kemoterapi Kombinasi antara Paclitaxel, Carboplatin, dan Ifosfamide (TIP) dengan Paclitaxel dan Carboplatin (TP) pada Kanker Serviks Stadium IIB. *Indonesian Journal of Obstetrics & Gynecology Science*, **6**(1), Article 1.
- Dasari, S., & Tchounwou, P. B. (2014). Cisplatin in cancer therapy: Molecular mechanisms of action. *European Journal of Pharmacology*, **740**, 364–378.

- Dear, T., Chiu, J., Meirovich, H., Malkin, A., Amjad, R., D'Souza, D., Callum, J., Leung, E., Kelly, K., Lazo-Langner, A., & Solh, Z. (2024). Are outcomes of locally advanced cervical cancer associated with prebrachytherapy hemoglobin values and transfusion practice? An observational study comparing two large academic centres with divergent clinical guidelines. *Brachytherapy*, **23**(6), 660–667.
- Federico, C., Sun, J., Muz, B., Alhallak, K., Cosper, P. F., Muhammad, N., Jeske, A., Hinger, A., Markovina, S., Grigsby, P., Schwarz, J. K., & Azab, A. K. (2021). Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side-Effect Profile. *International Journal of Radiation Oncology, Biology, Physics*, **109**(5), 1483–1494.
- Feng, T., Zhang, Y., Zheng, G., Lv, X., Yan, D., Feng, Y., & Lou, H. (2024). Efficacy and safety of cisplatin combined with paclitaxel concurrent radiotherapy in patients with locally advanced cervical squamous cell carcinoma. *Journal of Gynecologic Oncology*, **36**(1), e10.
- Fernando, A., Gatot, D., & Sitepu, Y. (2021). The Differences of Myelosuppression before and after Doxorubicin Chemotherapy in Breast Cancer Patients in Rsup. H. Adam Malik Medan. *International Journal of Research and Review*, **8**, 18–24.
- Ferrall, L., Lin, K. Y., Roden, R. B. S., Hung, C.-F., & Wu, T.-C. (2021). Cervical Cancer Immunotherapy: Facts and Hopes. *Clinical Cancer Research*, **27**(18), 4953–4973.
- Folorunso, S. A., Abiodun, O. O., Abdus-Salam, A. A., & Wuraola, F. O. (2023). Evaluation of side effects and compliance to chemotherapy in breast cancer patients at a Nigerian tertiary hospital. *Ecancermedicalscience*, **17**, 1537.
- Friyadi, M. H., & Askandar, B. (2014). *Perbandingan Operabilitas setelah Pemberian Kemoterapi Neoadjuvant Cisplatin dan Paclitaxel-Carboplatin pada Kanker Serviks IIB di Divisi Ginekologi Onkologi RSUD Dr. Soetomo*. **22**(1).
- Garza-Montúfar, M. E., Carballo-Rosario, G. D., & García-Pérez, C. M. (2024). Hydronephrosis and survival in cervical cancer patients: The role of urinary diversion. *Gynecologic Oncology Reports*, **57**, 101660.
- Gold, J. M., & Raja, A. (2025). Cisplatin. In *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK547695/>
- Guo, C., Zhan, B., Li, M.-Y., Yue, L., & Zhang, C. (2024). Association between oral contraceptives and cervical cancer: A retrospective case–control study based on the National Health and Nutrition Examination Survey. *Frontiers in Pharmacology*, **15**.
- Handa, S. I., & Freestone, S. (1990). Mefenamic acid-induced neutropenia and renal failure in elderly females with hypothyroidism. *Postgraduate Medical Journal*, **66**(777), 557–559.
- Hashiguchi, Y., Kasai, M., Fukuda, T., Ichimura, T., Yasui, T., & Sumi, T. (2015). Chemotherapy-induced neutropenia and febrile neutropenia in

- patients with gynecologic malignancy. *Anti-Cancer Drugs*, **26**(10), 1054–1060.
- Haverkos, H. W. (2005). Multifactorial Etiology of Cervical Cancer: A Hypothesis. *Medscape General Medicine*, **7**(4), 57.
- Hensley, M. L., Lebeau, D., Leon, L. F., Venkatraman, E., Waltzman, R., Sabbatini, P., Almadrones, L., Chi, D., & Spriggs, D. (2001). Identification of Risk Factors for Requiring Transfusion during Front-Line Chemotherapy for Ovarian Cancer. *Gynecologic Oncology*, **81**(3), 485–489.
- Homeopath, G. G. S. (2025, December 25). The Side Effects of CISPLATIN (CISPLATIN). *Biomedicus*. <https://biomedicus.gr/cisplatin-side-effects-7/>
- Huang, C.-Y., Cheng, M., Lee, N.-R., Huang, H.-Y., Lee, W.-L., Chang, W.-H., & Wang, P.-H. (2020). Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer. *International Journal of Environmental Research and Public Health*, **17**(7), 2213.
- Iversen, L., Fielding, S., Lidegaard, Ø., & Hannaford, P. C. (2021). Contemporary hormonal contraception and cervical cancer in women of reproductive age. *International Journal of Cancer*, **149**(4), 769–777.
- Kaosombatwattana, U., Limsrivilai, J., Pongpaibul, A., Maneerattanaporn, M., & Charatcharoenwitthaya, P. (2017). Severe enteropathy with villous atrophy in prolonged mefenamic acid users - a currently unrecognized in previously well-recognized complication: Case report and review of literature. *Medicine*, **96**(44), e8445.
- Kashyap, N., Krishnan, N., Kaur, S., & Ghai, S. (2019). Risk Factors of Cervical Cancer: A Case-Control Study. *Asia-Pacific Journal of Oncology Nursing*, **6**(3), 308–314.
- Kementerian Kesehatan Republik Indonesia. (2018). *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Serviks*. Kementerian Kesehatan RI.
- Kitagawa, R., Katsumata, N., Ando, M., Shimizu, C., Fujiwara, Y., Yoshikawa, H., Satoh, T., Nakanishi, T., Ushijima, K., & Kamura, T. (2012). A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. *Gynecologic Oncology*, **125**(2), 307–311.
- Kitagawa, R., Katsumata, N., Shibata, T., Kamura, T., Kasamatsu, T., Nakanishi, T., Nishimura, S., Ushijima, K., Takano, M., Satoh, T., & Yoshikawa, H. (2015). Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **33**(19), 2129–2135.
- Konnerth, D., Gaasch, A., Zinn, A., Rogowski, P., Rottler, M., Walter, F., Knoth, J., Sturdza, A., Oelmann, J., Grawe, F., Bodensohn, R., Belka, C., & Corradini, S. (2024). Hematologic Toxicity and Bone Marrow-

- Sparing Strategies in Chemoradiation for Locally Advanced Cervical Cancer: A Systematic Review. *Cancers*, **16**(10), 1842.
- Kumar, S., Mahdi, H., Bryant, C., Shah, J. P., Garg, G., & Munkarah, A. (2010). Clinical trials and progress with paclitaxel in ovarian cancer. *International Journal of Women's Health*, **2**, 411–427.
- Kurtin, S. (2012). Myeloid toxicity of cancer treatment. *Journal of the Advanced Practitioner in Oncology*, **3**(4), 209–224.
- Kusuma, F., Suryoadji, K. A., Purwoto, G., Wulandari, A. S., Sololan, G., Sini, K. P. I., Utami, T. W., Anggaraeni, T. D., Putra, A. D., Nuryanto, K. H., & Winarto, H. (2025). The Age as a Risk Factor for Advanced Stage in Cervical Cancer Patients at RSUPN Cipto Mangunkusumo 2019-2022: A Retrospective Multivariate Study. *Indonesian Journal of Obstetrics and Gynecology*, 65–70.
- Li, J., Li, Y., Wang, H., Shen, L., Wang, Q., Shao, S., Shen, Y., Xu, H., Liu, H., Cai, R., & Feng, W. (2023). Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer. *BMC Cancer*, **23**(1), 51.
- Liu, Z.-C., Liu, W.-D., Liu, Y.-H., Ye, X.-H., & Chen, S.-D. (2015). Multiple Sexual Partners as a Potential Independent Risk Factor for Cervical Cancer: A Meta-analysis of Epidemiological Studies. *Asian Pacific Journal of Cancer Prevention: APJCP*, **16**(9), 3893–3900.
- Lyman, G. H., Abella, E., & Pettengell, R. (2014). Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. *Critical Reviews in Oncology/Hematology*, **90**(3), 190–199.
- Mattiuzzi, C., & Lippi, G. (2020). Cancer statistics: A comparison between World Health Organization (WHO) and Global Burden of Disease (GBD). *European Journal of Public Health*, **30**(5), 1026–1027.
- McGuire, W. P., Blessing, J. A., Moore, D., Lentz, S. S., & Photopulos, G. (1996). Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **14**(3), 792–795.
- Medication Safety in Polypharmacy*. (2025). Retrieved July 7, 2025, from <https://www.who.int/docs/default-source/patient-safety/who-uhc-sds-2019-11-eng.pdf>
- Meitasari, A., Ermawati, D., Rohmani, S., Sasongko, H., Zulpadly, M., Utami, D., Susanto, N., Untari, M., & Darojati, U. (2025). Hematology Toxicities in Paclitaxel-Carboplatin Cancer Regimen. *Journal of Pharmaceutical Sciences and Community*, **22**, 51–58.
- Meixner, E., Wermes, L., Hoeltgen, L., von Diest, L. A., Sandrini, E., Harrabi, S., Seidensaal, K., Hoegen-Saßmannshausen, P., Vinsensia, M., König, L., Arians, N., Debus, J., & Hörner-Rieber, J. (2024). Hematologic Toxicity Profiles and the Impact of Hemoglobin Nadir and Transfusion on Oncologic Outcome in Definitive

- Radiochemotherapy for Cervical Cancer. *Cancers*, **16**(23), Article 23.
- Meyer-Wilmes, P., Kennes, L. N., Ignatov, A., Goetz, F., Wittenborn, J., Stickeler, E., & Tchaikovski, S. N. (2025). Earlier is not always better: Optimal time to initiate adjuvant chemotherapy after surgery for ovarian cancer. *Archives of Gynecology and Obstetrics*, **312**(4), 1163–1173.
- Moore, K. N., Herzog, T. J., Lewin, S., Giuntoli, R. L., Armstrong, D. K., Rocconi, R. P., Spannuth, W. A., & Gold, M. A. (2007). A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. *Gynecologic Oncology*, **105**(2), 299–303.
- Motwani, S. S., Kaur, S. S., & Kitchlu, A. (2022). Cisplatin Nephrotoxicity: Novel Insights Into Mechanisms and Preventative Strategies. *Seminars in Nephrology*, **42**(6), 151341.
- National Comprehensive Cancer Network. (2025). *NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (Version 4.2025)*. National Comprehensive Cancer Network (NCCN). https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf
- Obeagu, E. I. (2025). Anemia and hematocrit decline in cervical cancer: Unveiling clinical consequences and management strategies. *Annals of Medicine and Surgery*, **87**(9), 5784–5791.
- Okunaka, M., Kano, D., Matsui, R., Kawasaki, T., & Uesawa, Y. (2021). Comprehensive Analysis of Chemotherapeutic Agents That Induce Infectious Neutropenia. *Pharmaceuticals*, **14**(7), 681.
- Oun, R., Moussa, Y. E., & Wheate, N. J. (2018). The side effects of platinum-based chemotherapy drugs: A review for chemists. *Dalton Transactions (Cambridge, England: 2003)*, **47**(19), 6645–6653.
- Panigrahi, G., & Ambs, S. (2021). How Comorbidities Shape Cancer Biology and Survival. *Trends in Cancer*, **7**(6), 488–495.
- Pedoman Nasional Pelayanan Kedokteran (PNPK)*. (2018, October 17). <https://kemkes.go.id/id/pnpk-2018---tata-laksana-kanker-serviks>
- Perry, M. C. (2008). *The Chemotherapy Source Book*. Lippincott Williams & Wilkins.
- Putra, O. N. (2021). A cross sectional survey of side effects of antiretroviral (ARV) in outpatients HIV by Naranjo Algorithm. *Jurnal Ilmiah Farmasi*, **17**(1), Article 1.
- Rahman, S. A., & Arifuddin, S. (2019). *Therapeutic Response and Side Effects of Chemotherapy Combination Regimen Between Paclitaxel-Cisplatin and Paclitaxel-Carboplatin on Cervical Cancer Stage IIb*.
- Sagar, R. D., Madabhavi, I., & Revannasiddaiah, S. (2021). Correlation of Hematological Toxicity with the Bone Marrow Radiation Dose and Volume during Concurrent Chemo Radiation in Patients with Cervical Cancer. *Asian Pacific Journal of Cancer Care*, **6**(4), Article 4.
- Santana-Davila, R., Szabo, A., Arce-Lara, C., Williams, C. D., Kelley, M. J., & Whittle, J. (2014). Cisplatin versus carboplatin based regimens for

- the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*, **9**(5), 702–709.
- Šavrova, A., Jaal, J., Nõmm, O., & Innos, K. (2023). Factors associated with advanced-stage diagnosis of cervical cancer in Estonia: A population-based study. *Public Health*, **225**, 369–375.
- Schmitt, A., Gladieff, L., Laffont, C. M., Evrard, A., Boyer, J.-C., Lansiaux, A., Bobin-Dubigeon, C., Etienne-Grimaldi, M.-C., Boisdron-Celle, M., Mousseau, M., Pinguet, F., Floquet, A., Billaud, E. M., Durdux, C., Le Guellec, C., Mazières, J., Lafont, T., Ollivier, F., Concordet, D., & Chatelut, E. (2010). Factors for hematopoietic toxicity of carboplatin: Refining the targeting of carboplatin systemic exposure. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **28**(30), 4568–4574.
- Sharaeva, A. T., Zurdinova, A. A., & Satybaldieva, A. T. (2025). Risk assessment of adverse drug reactions in elderly patients with cardiovascular diseases: Study on diagnostic accuracy. *Heart, Vessels and Transplantation*, **9**(Issue 2), Article Issue 2.
- Shen, T., Zhao, J., Li, W., Wang, X., Gao, Y., Wang, Z., Hu, S., & Cai, J. (2023). Hypertension and hyperglycaemia are positively correlated with local invasion of early cervical cancer. *Frontiers in Endocrinology*, **14**, 1280060.
- Shields, T. S., Brinton, L. A., Burk, R. D., Wang, S. S., Weinstein, S. J., Ziegler, R. G., Studentsov, Y. Y., McAdams, M., & Schiffman, M. (2004). A Case-Control Study of Risk Factors for Invasive Cervical Cancer among U.S. Women Exposed to Oncogenic Types of Human Papillomavirus. *Cancer Epidemiology, Biomarkers & Prevention*, **13**(10), 1574–1582.
- Siwi, A. P., Andayani, N. G. P. S., & R, K. S. B. (2025). Gambaran profil pasien dan komorbiditas penyakit jantung hipertensi di Rumah Sakit Umum Daerah Klungkung tahun 2024. *Intisari Sains Medis*, **16**(3), 1532–1537.
- Smith, T. J., Bohlke, K., Lyman, G. H., Carson, K. R., Crawford, J., Cross, S. J., Goldberg, J. M., Khatcheressian, J. L., Leighl, N. B., Perkins, C. L., Somlo, G., Wade, J. L., Wozniak, A. J., Armitage, J. O., & American Society of Clinical Oncology. (2015). Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **33**(28), 3199–3212.
- Song, D., Kong, W., Zhang, T., Han, C., Liu, T., Jiao, S., & Chen, J. (2019). A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer. *Journal of Obstetrics and Gynaecology: The Journal of the Institute of Obstetrics and Gynaecology*, **39**(3), 389–394.

- Steben, M., & Duarte-Franco, E. (2007). Human papillomavirus infection: Epidemiology and pathophysiology. *Gynecologic Oncology, Reducing the Burden of HPV and HPV Related Diseases*, **107**(2, Supplement), S2–S5.
- T, F. S., Mona, J., Diana, S., Barry, B., Naomi, B., Soo, C., & Neil, P. (2011). *Does comorbidity explain the ethnic inequalities in cervical cancer survival in New Zealand? A retrospective cohort study.*
- Tao, W., Yang, J., Jiang, Y., Chen, W., & Wang, Y. (2020). Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis. *Dose-Response*, **18**(3), 1559325820941351.
- Tebeu, P.-M., Major, A. L., Rapiti, E., Petignat, P., Bouchardy, C., Sando, Z., Bernis, L. D. E., Ali, L., & Mhaweche-Fauceglia, P. (2008). The attitude and knowledge of cervical cancer by Cameroonian women; a clinical survey conducted in Maroua, the capital of Far North Province of Cameroon. *International Journal of Gynecological Cancer*, **18**(4), 761–765.
- Tewari, K. S., Java, J. J., Gatliffe, T. A., Bookman, M. A., & Monk, B. J. (2014). Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: An exploratory study of the Gynecologic Oncology Group. *Gynecologic Oncology*, **133**(3), 439–445.
- Wassie, M., Aemro, A., & Fentie, B. (2021). Prevalence and associated factors of baseline anemia among cervical cancer patients in Tikur Anbesa Specialized Hospital, Ethiopia. *BMC Women's Health*, **21**(1), 36.
- Wassie, M., Argaw, Z., Tsige, Y., Abebe, M., & Kisa, S. (2019). Survival status and associated factors of death among cervical cancer patients attending at Tikur Anbesa Specialized Hospital, Addis Ababa, Ethiopia: A retrospective cohort study. *BMC Cancer*, **19**(1), 1221.
- WHO. (2025). *Cervical cancer*. <https://www.who.int/news-room/fact-sheets/detail/cervical-cancer>.
- Wilson, J., Yao, G. L., Raftery, J., Bohlius, J., Brunskill, S., Sandercock, J., Bayliss, S., Moss, P., Stanworth, S., & Hyde, C. (2007). A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. *Health Technology Assessment*, **11**(13), 1–202, iii–iv.
- Wood, P. A., & Hrushesky, W. J. (1995). Cisplatin-associated anemia: An erythropoietin deficiency syndrome. *Journal of Clinical Investigation*, **95**(4), 1650–1659.
- Yamaguchi, M., Sekine, M., Hanley, S. J. B., Kudo, R., Hara, M., Adachi, S., Ueda, Y., Miyagi, E., & Enomoto, T. (2021). Risk factors for HPV infection and high-grade cervical disease in sexually active Japanese women. *Scientific Reports*, **11**, 2898.

- Zhang, L., Zheng, C., Cao, J., & Luo, S. (2020). Efficacy of paclitaxel, carboplatin, and bevacizumab for cervical cancer: A protocol for systematic review and meta-analysis. *Medicine*, **99**(24), e20558.
- Zhang, S., Xu, H., Zhang, L., & Qiao, Y. (2020a). Cervical cancer: Epidemiology, risk factors and screening. *Chinese Journal of Cancer Research*, **32**(6), 720–728.
- Zhang, W., Zhang, H., Gao, Y., Lei, J., & Suo, C. (2025). Fungi and cancer: Unveiling the complex role of fungal infections in tumor biology and therapeutic resistance. *Frontiers in Cellular and Infection Microbiology*, **15**.
- Zheng, Y., Tang, M., Deng, Z., & Cai, P. (2024). Genetic polymorphisms and platinum-induced hematological toxicity: A systematic review. *Frontiers in Pharmacology*, **15**.